We are live on ! Find out more
AIM

AIM ImmunoTech

35 hedge funds and large institutions have $16.8M invested in AIM ImmunoTech in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

201% more capital invested

Capital invested by funds: $5.6M → $16.8M (+$11.2M)

117% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 6

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

6% more funds holding

Funds holding: 3335 (+2)

Holders
35
Holders Change
+2
Holders Change %
+6.06%
% of All Funds
0.61%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
13
Reduced
6
Closed
7
Calls
Puts
Net Calls
Net Calls Change

AIM Hedge Fund Activity: Q1 2021 in Review

35 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2021, worth a combined $16.8M — up 201% from $5.6M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new AIM positions and 7 closed out — a net gain of 3 holders — while 13 added to existing stakes and 6 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $3.41M. The largest seller was Virtu Financial, cutting an estimated $168K.

  • 35 institutional investors held AIM ImmunoTech (AIM) as of Q1 2021, up from 33 in Q4 2020.
  • Funds reported $16.8M of AIM ImmunoTech stock for Q1 2021, up 201% quarter-over-quarter.
  • 10 funds opened new AIM ImmunoTech positions in Q1 2021 and 7 closed out, a net change of +3 holders.
  • The largest AIM ImmunoTech buyer in Q1 2021 was Morgan Stanley, an estimated $3.41M added.
  • The largest AIM ImmunoTech seller in Q1 2021 was Virtu Financial, an estimated $168K sold.

Based on aggregated 13F filings for Q1 2021.